BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by frankmanon Nov 26, 2024 3:40pm

49 Views

Post# 36332003

Level 2 bid ask 3:40

Ask
0.085	29,000	3
0.08	26,000	4
0.075	48,028	5
0.07	97,000	4
0.065	38,000	3
Bid
0.06	247,000	7
0.055	212,000	12
0.05	159,000	7
0.045	232,000	9